

Reference list:

Topic 1:

<p>Video 1</p>	<ol style="list-style-type: none"> 1. Vickers E. A Beginner's Guide to Targeted Cancer Treatments and Cancer Immunotherapy. 2nd Ed. Wiley Blackwell. <i>In press</i>. 2. Alexandrov L.B. et al. <i>Nature</i>, 2020; 578: 94-101. 3. Koh G. et al. <i>Nat Rev Cancer</i>. 2021; 21(10): 619-637. 4. Vogelstein B. et al. <i>Science</i>, 2013; 339(6127): 1546–1558.
<p>Video 2</p>	<ol style="list-style-type: none"> 1. Palmer S et al. <i>Proc Natl Acad Sci USA</i>. 2018; 115: 1883-1888. 2. Fane M & Weeraratna AT. <i>Nat Rev Cancer</i>. 2020; 20(2): 89-106. 3. Colom B et al. <i>Nat Genetics</i>. 2020; 52(6): 604-614. 4. Colom B et al. <i>Nature</i>. 2021; 598 (7881): 510-514. 5. Yizhak K et al. <i>Science</i>. 2019; 364 (6444): eaaw0726. 6. Martincorena I et al. <i>Science</i>. 2018; 362 (6417): 911-917. 7. Balkwill FR et al. <i>J Cell Sci</i>. 2012; 125: 5591-5596. 8. Gajewski TF et al. <i>Nat Immunol</i>. 2013; 14(10): 1014-1022. Shalpour S & Karin M. <i>J Clin Invest</i>. 2015; 125(9): 3347-3355. 9. Steeg P. S. <i>Nat Rev Cancer</i>. 2016; 16(4):201–218.
<p>Video 3</p>	<ol style="list-style-type: none"> 1. Burrell R. A. et al. <i>Nature</i>. 2013; 501(7467): 338-345. 2. Turner N.C. & Reis-Filho J.S. <i>Lancet Oncology</i>. 2012; 13(4): 70335-70337. 3. Kandoth C et al. <i>Nature</i>. 2013; 502: 333-339 4. Hodis E et al. <i>Cell</i>. 2012; 150(2): 251-263 5. Frank S et al. <i>F1000 Research</i>. 2018; 7:1173 6. Cicens J et al. <i>Cancers</i>. 2017; 9:42 7. Marine J-C et al. <i>Nature Reviews Cancer</i>. 2020: 743-756 8. Swanton C. <i>Cancer Res</i>. 2012; 72(19): 4875-4882. 9. McGranahan N & Swanton C. <i>Cell</i>. 2017; 168(4): 613-628. 10. Almagro J et al. <i>Trends in Cancer</i>. 2022; 8(6): 494-505

Topic 2:

Video 1	<ol style="list-style-type: none"> 1. G. A. Wintheiser and P. Silberstein, <i>Physiology, Tyrosine Kinase Receptors</i>. 2019. https://www.ncbi.nlm.nih.gov/books/NBK538532/ 2. Scitable, "Cell Signaling," Nature Education. https://www.nature.com/scitable/topicpage/cell-signaling-14047077/ 3. F. Sanchez-Vega <i>et al.</i> <i>Cell</i>. 2018; 173(2) doi: 10.1016/j.cell.2018.03.035. 4. J. G. Tate <i>et al.</i>, <i>Nucleic Acids Res</i>. 2019; 47(D1) doi: 10.1093/nar/gky1015. 5. Yip H.Y.K. & Papa A. <i>Cells</i>. 2021; 10(3): 659. 6. Fauvel B. & Yasri A. <i>MAbs</i>. 2014; 6(4): 838-851. 7. Naim N. et al. <i>Crit Rev Oncol Hematol</i>. 2021; 168: 103524
Video 2	<ol style="list-style-type: none"> 1. G. A. Wintheiser and P. Silberstein, <i>Physiology, Tyrosine Kinase Receptors</i>. 2019. https://www.ncbi.nlm.nih.gov/books/NBK538532/ 2. Scitable, "Cell Signaling," Nature Education. https://www.nature.com/scitable/topicpage/cell-signaling-14047077/ 3. F. Sanchez-Vega <i>et al.</i> <i>Cell</i>. 2018; 173(2) doi: 10.1016/j.cell.2018.03.035. 4. J. G. Tate <i>et al.</i>, <i>Nucleic Acids Res</i>. 2019; 47(D1) doi: 10.1093/nar/gky1015. 5. Yip H.Y.K. & Papa A. <i>Cells</i>. 2021; 10(3): 659. 6. Fauvel B. & Yasri A. <i>MAbs</i>. 2014; 6(4): 838-851. 7. Naim N. et al. <i>Crit Rev Oncol Hematol</i>. 2021; 168: 103524
Video 3	<ol style="list-style-type: none"> 1. Weiner L.M. et al. <i>Nat Rev Immunol</i>. 2010; 10(5): 317-327. 2. Weiner G.J. <i>Nat Rev Cancer</i>. 2015; 15: 361-370. 3. Wang Q. <i>et al.</i>, <i>Antibodies</i>. 2019; 8(3): 43. 4. June C.H. & Sadelain M. <i>N Engl J Med</i>. 2018; 379(1): 64-73. 5. Bianchini G. & Gianni L. <i>Lancet Oncol</i>. 2014; 15(2): e58-e68. 6. Elamin Y.Y. et al. <i>Cancer Microenviron</i>. 2015; 8(1): 15-21.
Video 4	<ol style="list-style-type: none"> 1. G. A. Wintheiser and P. Silberstein, <i>Physiology, Tyrosine Kinase Receptors</i>. 2019. https://www.ncbi.nlm.nih.gov/books/NBK538532/ 2. Scitable, "Cell Signaling," Nature Education. https://www.nature.com/scitable/topicpage/cell-signaling-14047077/ 3. F. Sanchez-Vega <i>et al.</i> <i>Cell</i>. 2018; 173(2) doi: 10.1016/j.cell.2018.03.035. 4. J. G. Tate <i>et al.</i>, <i>Nucleic Acids Res</i>. 2019; 47(D1) doi: 10.1093/nar/gky1015. 5. Hudis C.A., <i>N Engl J Med</i>. 2007; 357(1): 39-51. 6. Kreutzfeldt J. et al., <i>Am J Cancer Res</i>. 2020; 10(4): 1045-1067. 7. Cai W.Q. <i>et al.</i> <i>Frontiers in Oncology</i>, 2020; 10: doi: 10.3389/fonc.2020.01249. 8. Cho B. C. et al., <i>Clin Lung Cancer</i>. 2023; 24(2): 89-97. 9. Chau C. H. et al. <i>Lancet</i> 2019; 394(10200): 793-804. 10. Tarantino P. et al. <i>Nat Rev Clin Oncol</i>. 2023; 20(8): 558-576

<p>Video 5</p>	<ol style="list-style-type: none"> 1. Hou Z. & Liu H. <i>Cells</i>. 2023; 12(6): 925 2. Key Learning Points: ESMO Consensus Statement on EGFR Mutations in Non-small Cell Lung Cancer - <i>Medscape</i> - 09 May 2023. 3. Yuan M. et al. <i>Signal Trans Targ Ther</i>. 2019; 4: 61 4. Conlon N.T. et al. <i>British J Cancer</i>. 2021; 124: 1249-1259 5. Halle B. R. & Johnson D. B. <i>Curr Treat Options Oncol</i>. 2021; 22(4): 30 6. Réa D. & Hughes T. P. <i>Crit Rev Oncol Hematol</i>. 2022; (171): 103580 7. Remon J et al. <i>Cancer Treat Rev</i>. 2021; 95: 102178 8. Zhong L. <i>Signal Trans Targ Ther</i>. 2021; 6(1): 201 9. Moore A. R. & Malek S. <i>Cancer Cell</i>. 2021; 39(8): 1059-1061 10. Suryadinata R. et al. <i>Biosci Rep</i>. 2010; 30: 243-255 11. Shah M. et al. <i>Oncology (Williston Park)</i>; 2019: 32(5): 216-222
<p>Video 6</p>	<ol style="list-style-type: none"> 1. Hanahan D. & Weinberg R.A. <i>Cell</i>. 2000; 100(1): 57-70. 2. Hanahan D. & Weinberg R.A. <i>Cell</i>. 2011; 144: 646-674. 3. D. Hanahan. <i>Cancer Discovery</i>. 2022; 12(1): 31-46. 4. Plummer R. <i>Breast Cancer Res</i>. 2011;13(4): 218. 5. Konecny G.E. & Kristeleit R.S. <i>Br J Cancer</i>. 2016; 115: 1157-1173. 6. Brown J.S. et al. <i>Cancer Discov</i>. 2017; 7(1): 20-37. 7. Jiang X. et al. <i>Cancer Manag Res</i>. 2019; 11: 4371-4390 8. Dhawan M. et al. <i>The Oncologist</i>. 2016; 21: 940-945. 9. Clancy S. <i>Nature Education</i> 2008: 1(1):103. 10. Wright W.D. et al. <i>J Biol Chem</i>. 2018; 293(27): 10524-10535. 11. Cousineau I. <i>Mol Genet Genomics</i>. 2011; 285: 325-340. 12. D'Andrea A. <i>DNA Repair</i>. 2018; 71: 172-176. 13. Konstantinopoulos P.A. et al. <i>Cancer Discov</i>. 2015; 5(11): 1137-1154. 14. Cortesi L. et al. <i>Target Oncol</i>. 2021; 16(3): 255-282. 15. Winter C. et al. <i>Ann Oncol</i>. 2016; 27(8): 1532-1538. 16. Robinson D. et al. <i>Cell</i> 2015; 161: 1215-1228.
<p>Video 7</p>	<ol style="list-style-type: none"> 1. Jayson G. C. et al. <i>Lancet</i>. 2016; 388(10043): 518-529. 2. Sunder S.S. et al. <i>Signal Transd Targeted Ther</i>. 2023; 8: 262. 3. Clark L et al. <i>Cancers (Basel)</i>: 2024; 16(1): 31. 4. Pezzella F. <i>Cancer Drug Resistance</i>. 2019; 2(3): 595-607. 5. Cowey C.L. & Rathmell W.K. <i>Curr Oncol Rep</i>. 2009; 11(2): 94-101. 6. Ren X. et al. <i>Mol Pharmacol</i>. 2022; 102(6): 240-247.

Topic 3:

<p>Video 1</p>	<ol style="list-style-type: none"> 1. Hanahan D. & Weinberg R.A. <i>Cell</i>. 2000; 100(1): 57-70. 2. Swann J.B. & Smyth M.J. <i>J Clin Invest</i>. 117(5): 1137-1146 3. Shuel S.L. <i>Can Fam Physician</i>. 2022; 68(7): 515-518 4. Website of the National Cancer Institute. Targeted Therapy to Treat Cancer https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies 5. Website of the National Cancer Institute. Immunotherapy to Treat Cancer https://www.cancer.gov/about-cancer/treatment/types/immunotherapy
<p>Video 2</p>	<ol style="list-style-type: none"> 1. Leone P et al. <i>JNCI</i>. 2013; 105(16): 1172-1187. 2. Kumar BV et al. <i>Immunity</i> 2018; 48(2): 202-213. 3. British Society for Immunology website. Dendritic Cells. https://www.immunology.org/public-information/bitesized-immunology/cells/dendritic-cells 4. Chen D.S. & Mellman I. <i>Immunity</i> 2013; 39(1): 1-10.
<p>Video 3</p>	<ol style="list-style-type: none"> 1. Leone Mittal D. et al. <i>Curr Opin Immunol</i>. 2014; 27: 16-25. 2. Schreiber R.D. et al. <i>Science</i> 2011; 331(6024): 1565-1570. 3. Dunn G.P. et al. <i>Immunity</i> 2004; 21(2): 137-148. 4. Muenst S. et al. <i>J Internal Med</i>. 2016; 279: 541-562. 5. Gajewski T.F. et al. <i>Nature Immunol</i>. 2013; 14(10): 1014-1022. 6. Shalapour S. & Karin M. <i>J Clin Invest</i>. 2015; 125(9): 3347-3355. 7. Komi D.E.I. & Redegeld F.A. <i>Clin Rev All Immunol</i>. 2020; 8(2): 208. 8. Mantovani A. et al. <i>Nat Rev Drug Discov</i>. 2022; 21(11): 799-820 9. Melaiu O. et al. <i>Front Immunol</i>. 2020; 10: DOI=10.3389/fimmu.2019.03038 10. Truong L-H. & Pauklin S. <i>Cancers</i>. 2021; 13(19): 5028. 11. Salmon H. et al. <i>Nat Rev Cancer</i>. 2019; 19: 215-227. 12. Teillaud J-L. et al. <i>Front Immunol</i>. 2017; 8: 830. 13. Fridman W.H. et al. <i>Nat Rev Cancer</i> 2012; 12: 298-306. 14. Fridman W.H. et al. <i>Nat Rev Clin Oncol</i> 2017; 14: 717-734. 15. Larsen S.K. et al. <i>Crit Rev Oncol</i> 2014; 19(0): 91-105.

Video 4	<ol style="list-style-type: none"> 1. Chen D.S. & Mellman I. <i>Immunity</i> 2013; 39(1): 1-10. 2. Vinay DS, et al. <i>Seminars in Cancer Biology</i> 2015; 35: S185–S198. 3. Motz GT & Coukos G. <i>Immunity Rev.</i> 2013; 39: 61-73. 4. Topalian S et al. <i>Cancer Cell</i> 2015; 27: 450-461. 5. Chow A et al. <i>Nat Rev Clinical Oncol.</i> 2022; 19: 775-790. 6. Munhoz RR & Postow MA. <i>F1000Research.</i> 2016; 5: 2545. 7. Marin-Acevedo JA et al. <i>J Hematol Oncol.</i> 2018; 11:8. 8. Schaaf M.B. et al. <i>Cell Death Dis.</i> 2018; 9(2): 115 9. Baulu E et al. <i>Sci Adv.</i> 2023; 9(7): eadf3700 10. Website of the National Cancer Institute: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
----------------	---

Topic 4:

Video 1	<ol style="list-style-type: none"> 1. Topalian S.L. et al. <i>Cancer Cell.</i> 2015; 27(4): 450-461. 2. Website of the National Cancer Institute. Immune Checkpoint Inhibitors: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors 3. Shiravand Y. et al. <i>Curr Oncol.</i> 2022; 29(5): 3044-3060 4. Popovic A. et al. <i>J Clin Invest.</i> 2018; 128(8): 3209-3218. 5. Kraehenbuehl L. et al. <i>Nat Rev Clin Oncol.</i> 2022; 19(1): 37-50.
Video 2	<ol style="list-style-type: none"> 1. Waldman A.D. et al. <i>Nat Rev Immunol.</i> 2020; 20: 651-668. 2. Wei S.C. et al. <i>Cancer Discov.</i> 2018; 8(9): 1069-1086. 3. Nagasaki J. et al. <i>Cancer Sci.</i> 2022; 113(10): 3303-3312. 4. van Weverwijk A. & de Visser K.E. <i>Nat Rev Cancer.</i> 2023; 23(4):193–215. 5. Chen D. S. & Mellman I. <i>Nature.</i> 2017; 541(7637):321–330 6. McGranahan N. & Swanton C. <i>Sci Transl Med.</i> 2019; 11(506): eaax7918 7. Ebelt D. & Manuel E.R. <i>Semin Cancer Biol.</i> 2019; 59: 236-250. 8. Vogelstein B. et al. <i>Science,</i> 2013; 339(6127): 1546–1558.

<p>Video 3</p>	<ol style="list-style-type: none"> 1. Haslam A. & Prasad V. <i>JAMA Netw Open</i>. 2019; 2(5): e192535. 2. Truong L-H. & Pauklin S. <i>Cancers</i>. 2021; 13(19): 5028. 3. Salmon H. et al. <i>Nat Rev Cancer</i>. 2019; 19: 215-227. 4. Teillaud J-L. et al. <i>Front Immunol</i>. 2017; 8: 830. 5. Fridman W.H. et al. <i>Nat Rev Cancer</i>. 2012; 12: 298-306. 6. Fridman W.H. et al. <i>Nat Rev Clin Oncol</i>. 2017; 14: 717-734. 7. Larsen S.K. et al. <i>Crit Rev Oncol</i>. 2014; 19(0): 91-105. 8. Petitprez F. et al. <i>Nat Rev Cancer</i>. 2019; 19(6), 307-325. 9. Vanhersecke L. et al. <i>Nature Cancer</i>. 2021; 2(8), 794-802. 10. Ferris R.L. et al. (2016). <i>N Engl J Med</i>. 375: 1856-1867. 11. Cohen E.E. et al. (2018). <i>Lancet</i>. 2019; 393(10167): 156-167. 12. Motzer R.J. et al. (2015). <i>N Engl J Med</i>. 373: 1803-1813. 13. Bellmunt J. et al. (2017). <i>N Engl J Med</i>. 376: 1015-1026. 14. Sharma P. et al. (2017). <i>Lancet Oncol</i>. 18(3): 312-322. 15. Zhu A.X. et al. (2018). <i>Lancet Oncol</i>. 19(7): 940-952. 16. Eng C. et al. <i>Lancet Oncol</i>. 2019; 20(6): 849-861. 17. Matulonis U.A. et al. <i>Annals Oncol</i>. 2019; 30(7): 1080-87. 18. Chung H.C. et al. <i>J Clin Oncol</i>. 2019; 37(17): 1470-1478. 19. Fashoyin-Aje L. et al. <i>Oncologist</i>. 2019; 24(1): 103-109. 20. Garon E.B. et al. <i>J Clin Oncol</i>. 2019; 37 (suppl; abstr LBA9015). 21. Adams S. et al. <i>Annals Oncol</i>. 2019; 30(3): 397-404. 22. Adams S. et al. <i>Annals Oncol</i>. 2019; 30(3): 405-411. 23. Versluis J. et al. <i>Nat Med</i>. 2020; 26(4): 475-484. 24. Patel S. et al. <i>N Engl J Med</i>. 2023; 388(9): 813-823.
<p>Video 4</p>	<ol style="list-style-type: none"> 1. Havel J.J. et al. <i>Nat Rev Cancer</i>. 2019; 19(3): 133-150. 2. Wang C. et al. <i>J Cancer</i>. 2022; 13(2):481-495. 3. Bai R. et al. <i>Biomark Res</i>. 2020; 8(1):34. 4. Grigg C. & Rizvi N.A. <i>J Immunother Cancer</i>. 2016; 4:48. 5. Doroshow D.B. et al. <i>Nat Rev Clin Oncol</i>. 2021; 18(6): 345-362. 6. Garon E.B. et al. <i>N Engl J Med</i>. 2015; 372: 2018-28. 7. Grigg C. & Rizvi N.A. <i>J Immunother Cancer</i>. 2016; 4: 48. 8. Nishino M. et al. <i>Nat Rev Clin Oncol</i>. 2017; 14(11): 655-668. 9. Thunnissen E. et al. <i>Mod Pathol</i>. 2019, 33: 792-801. 10. Yarchoan M. et al. <i>N Engl J Med</i>. 2017; 377:25. 11. Yarchoan M. et al. <i>JCI Insight</i>. 2019; 4(6): e126908 12. Bonneville R. et al. <i>JCO Precision Oncology</i>. 2017; 2017: PO.17.00073. 13. Malczewski A.B. et al. <i>Front Immunol</i>. 2021; 12: 624434. 14. Cortellini A. et al. <i>J Immunother Cancer</i>. 2020; 8(2): e001361. 15. Kumar P. et al. <i>Cancer Metastasis Rev</i>. 2022; 41(2): 261-280. 16. Landre T. et al. <i>ESMO Open</i>. 2024; 9(2): 102220

Video 5	<ol style="list-style-type: none"> 1. Chen D.S. & Mellman I. <i>Nature</i>. 2017; 541(7637): 321–330. 2. Raskov H. et al. <i>British J Cancer</i>. 2021; 124: 359-367. 3. Benoit A. et al. <i>Cells</i>. 2023; 12(13): 1787. 4. Palmer A.C. & Sorger P.K. <i>Cell</i>. 2017; 171(7): 1678-1691. 5. Yap T.A. et al. <i>Cancer Discov</i>. 2021; 11(6): 1368-1397. 6. Larkin J. <i>N Eng J Med</i>. 2019; 381:1535-1546 7. Tun AM et al. <i>Future Science</i>. 2019; 5(9): FSO421 8. Grant MJ et al. <i>Nat Rev Clin Oncol</i>. 2021; 18: 625-644 9. Rini B. et al. <i>J Clin Oncol</i>. 2021; 39 (15_suppl): 4500. 10. Choueiri T.K. et al. <i>Ann Oncol</i>. 2020; 31(8): 1030-1039. 11. Haanen J.B.A.G. et al. <i>ESMO Open</i>. 2023; 8(3): 101210. 12. Motzer R.J. et al. <i>Cancer</i>. 2022; 128(11): 2085-2097.
----------------	--

Topic 5:

Video 1	<ol style="list-style-type: none"> 1. Pavlasova G. & Mraz M. <i>Haematologica</i>. 2020; 105(6): 1494-1506. 2. Van de Donk N.W.C.J. & Usmani S.Z. <i>Front Immunol</i>. 2018; 9: 2134. 3. Redman J.M. et al. <i>Mol Immunol</i>. 2015; 67(2A): 28-45. 4. Goebeler M.A. & Bargou R.C. <i>Nat Rev Clin Oncol</i>. 2020; 17: 418-434. 5. Wang Q. et al., <i>Antibodies</i>. 2019; 8(3): 43.
Video 2	<ol style="list-style-type: none"> 1. June C.H. & Sadelain M. <i>N Engl J Med</i>. 2018; 379(1): 64-73. 2. Rafiq S. et al. <i>Nat Rev Clin Oncol</i>. 2020; 17: 147-167. 3. Wei J. et al. <i>J Hematol & Oncol</i>. 2019; 12: 62. 4. Lemoine J. et al. <i>J Hematol Oncol</i>. 2021; 14: 199. 5. Sterner R.C. & Sterner R.M. <i>Blood Cancer J</i>. 2021; 11(4): 69. 6. Qasim W. <i>Blood</i>. 2023; 141(8): 835-845. 7. Lopez-Cantillo G. et al. 2022; <i>Front Immunol</i>. 13: 878209. 8. Yang Y. et al. <i>Transl Cancer Res</i>. 2020; 9(11): 7310-7322. 9. Hawkins E.R. et al. <i>Biologics</i>. 2021; 15: 95-105. 10. Xie B. et al. <i>Cancers (Basel)</i>. 2022; 14(13): 3230. 11. van der Schans J.J. et al. <i>Front Oncol</i>. 2020; 10: 1362.
Video 3	<ol style="list-style-type: none"> 1. B Cells and Antibodies, in <i>Molecular Biology of the Cell</i>. 4th edition. Alberts B et al. New York: Garland Science; 2002. 2. Efremov D.G. et al. <i>Cancers</i>. 2020; 12(6): 1396. 3. Burger J.A. & Wiestner A. <i>Nat Rev Cancer</i>. 2018; 18: 148-167. 4. Nguyen P.H. et al. <i>Leukemia</i>. 2019; 33(3): 576-587. 5. Kaplon H. & Reichart J.M. <i>Mabs</i>. 2019; 11(2): 219-238. 6. Aubrey B.J. et al. <i>Cell Death Diff</i>. 2018; 25: 104-113. 7. McIlwain D.R. et al. <i>Cold Spring Harb Perspect Biol</i>. 2013; 5: a008656 8. Perini G.F. et al. <i>J Hematol Oncol</i>. 2018; 11(1): 65. 9. Kapoor I. et al. <i>Cell Death & Disease</i>. 2020; 11: 941.

<p>Video 4</p>	<ol style="list-style-type: none"> 1. Nutt S.L. et al. <i>Nat Rev Immunol.</i> 2015; 15: 160-171. 2. Morgan G.J. et al. <i>Nat Rev Cancer.</i> 2012; 12: 335-348. 3. Xu L et al. <i>Cell Death Discov.</i> 2024; 10: 55. 4. Navon A. & Ciechanover A. <i>J Biol Chem.</i> 2009; 284: 33713-33718. 5. Livneh I. et al. <i>Cell Res.</i> 2016; 26: 869-885. 6. Thibaudeau T.A. & Smith D.M. <i>Pharm Reviews.</i> 2019; 71(2): 170-197. 7. Glickman M.H. & Ciechanover A. <i>Phys Reviews.</i> 2002; 82(2): 373-428. 8. Harper J.W. & Bennett E.J. <i>Nature.</i> 2016; 537(7620): 328-338. 9. Ito S. <i>Cancers (Basel).</i> 2020; 12(2): 265. 10. Crawford L.J. et al. <i>J Cell Commun Signal.</i> 2011; 5: 101-110. 11. Faver I.R. et al. <i>Int J Dermatol.</i> 2005; 44(1): 61-67 12. Holstein S.A. & McCarthy P.L. <i>Drugs.</i> 2017; 77(5): 505-520. 13. Ito T. et al. <i>Cell Chem Biol.</i> 2021; 28(7): 987-999. 14. Hideshima T. et al. <i>Nat Rev Cancer.</i> 2007; 7: 585-598. 15. Ribatti D. & Vacca A. <i>Int J Mol Sci.</i> 2018; 19(7): 2031.
<p>Video 5</p>	<ol style="list-style-type: none"> 1. Braun T.P. et al. <i>Cancer Cell.</i> 2020; 37: 530-542. 2. Hughes T.P. et al. <i>N Engl J Med.</i> 2019; 381(24): 2315-2326. 3. Leoni V. & Biondi A. <i>Haematologica.</i> 2015; 100(3): 295-299. 4. Rea D. & Hughes T.P. <i>Crit Rev Oncol/Hematol.</i> 2022; 171: 103580. 5. Carter J.L. et al. <i>Signal Transduct targeted ther.</i> 2020; 5: 288. 6. Desai R.H. et al. <i>Cancers (Basel).</i> 2022; 14(9): 2182. 7. Williams B.A. et al. <i>J Clin Med.</i> 2019; 8(8): 1261. 8. Guy D. & Uy G.L. <i>Curr Hematol Oncol Malig Rep.</i> 2018; 13(6): 417-425. 9. Stanchina M. et al. <i>Cancers.</i> 2020; 12: 3225. 10. Burnett A. & Stone R. <i>Clin Lymph Myeloma Leukem.</i> 2020; 20(6): 341-350. 11. Larrosa-Garcia M. & Baer M.R. <i>Mol Cancer Ther.</i> 2017; 16(6): 991-1001.